Board of Directors

George Hodgin is the Founder and CEO of BRC. He is a former Navy SEAL officer and alumnus of the Stanford University Graduate School of Business. He was commissioned as an officer in the Navy in 2009, after earning a BA in Economics and Mandarin from the University of North Carolina at Chapel Hill, where he was a Morehead-Cain scholar. George led SEALs in combat in counter-terrorism operations in Afghanistan and Southeast Asia.

Mr. Imasogie has over 30 years of experience in the fields of law, finance and business management, healthcare, and the pharmaceutical industry. Prior to co-founding PIPV Capital, a Private Equity firm focused on the Life Sciences space, in which he is the Senior Managing Partner, Mr. Imasogie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President.

Dr. Charles Schumacher is a fellowship-trained, board-certified orthopedic surgeon whose clinical practice and research have focused on the treatment of complex pain conditions, including inflammatory, neuropathic, and central nervous system-mediated pain disorders. Throughout his career, he has treated patients suffering from Complex Regional Pain Syndrome (CRPS), chronic musculoskeletal pain, and other debilitating conditions for which effective therapeutic options remain limited.

Dr. Schumacher earned his medical degree from LSU Health Sciences Center and completed a General Surgery Internship and Orthopedic Residency through the Harvard Combined Orthopaedic Residency Program at Massachusetts General Hospital, where he served as Chief Resident. He subsequently completed a Fellowship in Joint Replacement and Reconstruction at Stanford University, where he participated in multiple research collaborations, followed by a Traveling Hip Fellowship in Zürich, Switzerland. In addition to his clinical practice, Dr. Schumacher has contributed to research examining opioid use and addiction, providing valuable perspective on the need for effective non-opioid therapies to address chronic pain. His firsthand experience caring for patients with severe pain conditions aligns closely with BRC Therapeutics’ mission to develop novel cannabinoid-based medicines for patients suffering from unmet medical needs, including CRPS and other chronic pain disorders.

Dr. Schumacher also serves on the Board or Executive Committee of the YMCA of Greater New Orleans, AVALA Hospital, St. Scholastica Academy, and the Harvard Orthopaedic Alumni Association. He is a Founding Physician of the Gillian Reny Stepping Strong Center for Trauma Innovation.

Howard Goodwin is Managing Partner at Intrinsic Capital Partners. Dr. Goodwin has been investing in private and public equites for over 20 years. Prior to co-founding Intrinsic Capital Partners, Dr. Goodwin demonstrated an acumen investing in life science & technology businesses at top investment firms, including Maverick Capital, Citadel Investments and, most recently, as a portfolio manager at Millennium Partners. Dr. Goodwin began his investment career at Graham Partners, a middle-market private equity firm. Prior to beginning his investment career, Dr. Goodwin earned his medical degree from Thomas Jefferson University and undergraduate degree from Princeton University.

Mr. Vikas Desai serves as Chief Executive Officer & Chairman at Achari Ventures Holdings Corp. He is the Founder and serves as a Partner at Achari Ventures. He served as Board Member at Komplyd. He serves as Board Member at Willow Industries, Apex Trading, and AG Gas. Previously he served as a private equity investor at Oaktree Capital Management. Prior to that, he worked at Morgan Stanley. He holds a B.S. in Finance and Environmental Studies from the Stern School of Business.

Mr. Eastman has over 40 years of experience building healthcare businesses. He is a Senior Advisor at EW Healthcare Partners, where he previously served as Managing Director across multiple funds and led investments in ProteinSimple (acquired by Bio-Techne), Corium (acquired by Gurnet Point), EyePoint Pharmaceuticals, and Elusys Therapeutics (acquired by Heat Biologics).

Earlier in his career, Mr. Eastman served as CEO of Geron, growing the company from a venture-backed startup to a publicly traded pioneer in regenerative medicine and cancer, and as CEO of Rinat Neuroscience, a Genentech spin-out focused on large molecule drugs for nervous system disorders that was acquired by Pfizer in 2006. He began his career at American Cyanamid Company (now Pfizer), where he spent 15 years managing pharmaceutical products, divisions, and subsidiaries in the U.S. and overseas. Mr. Eastman holds a B.A. from Williams College and an M.B.A. from Columbia University.